Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohortPauline Tétu, Célèste Lebbé, Clara Allayous et al.|European Journal of Cancer|2019Cited by 35
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control studyLéo Plaçais, Célèste Lebbé, Julie De Quatrebarbes et al.|Annals of the Rheumatic Diseases|2022Cited by 34
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆Y. Di Filippo, Henri Montaudié, Stéphane Dalle et al.|Annals of Oncology|2020Cited by 30
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanomaPauline Tétu, Célèste Lebbé, Joanna Mangana et al.|European Journal of Cancer|2018Cited by 14
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalA. Vallet, Bastien Oriano, Laurent Mortier et al.|JAMA Dermatology|2019Cited by 10